These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 33288923)

  • 1. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nachbagauer R; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Stadlbauer D; Wilson PC; Aydillo T; Behzadi MA; Bhavsar D; Bliss C; Capuano C; Carreño JM; Chromikova V; Claeys C; Coughlan L; Freyn AW; Gast C; Javier A; Jiang K; Mariottini C; McMahon M; McNeal M; Solórzano A; Strohmeier S; Sun W; Van der Wielen M; Innis BL; García-Sastre A; Palese P; Krammer F
    Nat Med; 2021 Jan; 27(1):106-114. PubMed ID: 33288923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
    Bernstein DI; Guptill J; Naficy A; Nachbagauer R; Berlanda-Scorza F; Feser J; Wilson PC; Solórzano A; Van der Wielen M; Walter EB; Albrecht RA; Buschle KN; Chen YQ; Claeys C; Dickey M; Dugan HL; Ermler ME; Freeman D; Gao M; Gast C; Guthmiller JJ; Hai R; Henry C; Lan LY; McNeal M; Palm AE; Shaw DG; Stamper CT; Sun W; Sutton V; Tepora ME; Wahid R; Wenzel H; Wohlbold TJ; Innis BL; García-Sastre A; Palese P; Krammer F
    Lancet Infect Dis; 2020 Jan; 20(1):80-91. PubMed ID: 31630990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
    Bliss CM; Nachbagauer R; Mariottini C; Cuevas F; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Innis BL; García-Sastre A; Palese P; Krammer F; Coughlan L
    EBioMedicine; 2024 Jun; 104():105153. PubMed ID: 38805853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.
    Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA
    Front Immunol; 2019; 10():756. PubMed ID: 31105689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity.
    Meade P; Strohmeier S; Bermúdez-González MC; García-Sastre A; Palese P; Simon V; Krammer F
    J Virol; 2023 Jan; 97(1):e0107022. PubMed ID: 36533948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
    Choi A; Bouzya B; Cortés Franco KD; Stadlbauer D; Rajabhathor A; Rouxel RN; Mainil R; Van der Wielen M; Palese P; García-Sastre A; Innis BL; Krammer F; Schotsaert M; Mallett CP; Nachbagauer R
    Immunohorizons; 2019 Apr; 3(4):133-148. PubMed ID: 31032479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
    Krammer F; Palese P
    J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study.
    Nachbagauer R; Krammer F; Albrecht RA
    Vaccines (Basel); 2018 Jul; 6(3):. PubMed ID: 30044403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.
    Ermler ME; Kirkpatrick E; Sun W; Hai R; Amanat F; Chromikova V; Palese P; Krammer F
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28356526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
    Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
    Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.
    Isakova-Sivak I; Korenkov D; Smolonogina T; Kotomina T; Donina S; Matyushenko V; Mezhenskaya D; Krammer F; Rudenko L
    Virology; 2018 May; 518():313-323. PubMed ID: 29574336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.
    Tete SM; Jul-Larsen Å; Rostami S; Lunde THF; Søland H; Krammer F; Cox RJ
    Vaccine; 2018 Apr; 36(16):2213-2219. PubMed ID: 29548607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    Carter NJ; Plosker GL
    BioDrugs; 2008; 22(5):279-92. PubMed ID: 18778110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial.
    Cheng A; Hsieh SM; Pan SC; Li YH; Hsieh EF; Lee HC; Lin TW; Lai KL; Chen C; Shi-Chung Chang S; Chang SC
    J Microbiol Immunol Infect; 2019 Oct; 52(5):685-692. PubMed ID: 31255574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.
    Qiu Y; Stegalkina S; Zhang J; Boudanova E; Park A; Zhou Y; Prabakaran P; Pougatcheva S; Ustyugova IV; Vogel TU; Mundle ST; Oomen R; Delagrave S; Ross TM; Kleanthous H; Qiu H
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31826999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.